Navigation Links
Sinovac's CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
Date:12/28/2009

BEIJING, Dec. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA), a leading provider of biopharmaceutical products in China, announced today that Weidong Yin, Chairman, President & CEO, was presented with the Annual Innovation Award by China Central Television (CCTV). As previously announced, Mr. Yin had been one of 18 nominees for the CCTV's China's 2009 Economic Man-of-the-Year. Results were announced on December 23, 2009 at an award ceremony held in Beijing.

Mr. Weidong Yin was honored because of his contribution to the battle against the H1N1 influenza pandemic; Sinovac vaccines protect human life and strengthen the Chinese people's confidence.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "I am very pleased to have received CCTV's 2009 Annual Innovation Award. As the first company worldwide to receive approval for the H1N1 vaccine, we have exemplified Sinovac's position as a true innovator in the global vaccine industry. We are proud that our entire portfolio of innovative vaccines continues to make a significant contribution to the health and well-being of Chinese citizens."

Recipients of the Top Ten 2009 Economic Man-of-the-Year award were CEO and president of Sina Charles Chao, China Minsheng Banking Corporation Chairman Dong Wenbiao, Shenzhen Capital Group Chairman Jin Haitao, chairman of Geely Automobile Holding Li Shufu, Guangdong Galanz Enterprise Group CEO Liang Chao-Hsien, chairman of Jiangsu Shagang Group Shen Wenrong, chairman and CEO at Neusoft Group Ltd Liu Jiren, Phoenix Publishing & Media Group chairman Tan Yue, Chongqing Changan Automobile Co., Ltd., chairman Xu Liuping, and chairman of New Oriental Education Group Yu Minhong. In addition, Liu Haitao, head of Shanghai Institute of Microsystem and Information Technology under the Chinese Academy of Sciences, received the Annual Innovation Award.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccine.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

     Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

     Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
3. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
4. Additional Data From Fidaxomicins Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting
5. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
6. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
7. Micromet to Host Conference Call and Webcast to Discuss MT110 Data Presented at ECCO/ESMO on September 22, 2009
8. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting
9. Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting
10. Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
11. $10,000 ISSAC Award for Innovation Presented to MIT PhD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 2017 , ... Having worked on the design of the innovative Triton™ ... to top lab design architects from around the country at the Lab Design Conference ... and Engineering Greg Casey will be at the show, where they will highlight the ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative Technology Center, ... emerging bio and technology start-ups, is hosting “Celebration Friday” (a festive gathering highlighting ... start with libations and networking at 3:30 p.m. at FITCI’s 4539 Metropolitan Court ...
(Date:4/20/2017)... 20, 2017  Eli Lilly and Company (NYSE: ... galcanezumab for the prevention of migraine at the American ... place April 22-28, 2017, in Boston ... at AAN, including safety and patient outcomes data for ... a reduction in monthly migraine headache days among patients ...
(Date:4/20/2017)... , April 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. ... new results at the International Liver Congress ("ILC") 2017 of ... in Amsterdam on the positive effects ... mouse model of obesity and metabolic syndrome. ... According to Dr. Lyne Gagnon, Vice-President of ...
Breaking Biology Technology:
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
(Date:3/7/2017)... 2017   HireVue , the leading provider of ... the best talent, faster, today announced the additions of ... and Diana Kucer as Chief Marketing Officer ... team poised to drive continued growth in the company,s ... of record bookings in 2017. "Companies worldwide ...
Breaking Biology News(10 mins):